Red Light Therapy for Vision Improvement

Your eyes are among the most metabolically active organs in your body. The retina consumes oxygen at a rate comparable to the brain, and its photoreceptor cells contain more mitochondria per cell than almost any other tissue. This extraordinary energy demand makes the eyes uniquely vulnerable to age-related mitochondrial decline — and uniquely responsive to red light therapy.

Over the past decade, pioneering research from University College London and institutions worldwide has demonstrated that brief exposures to specific wavelengths of red and near-infrared light can measurably improve visual function. Below we examine the science, the key studies, and how to apply this knowledge safely.

Why Vision Declines with Age

To understand how red light therapy helps, you need to understand what goes wrong.

Mitochondrial Decline in the Retina

Retinal photoreceptors — the rods and cones that detect light — are packed with mitochondria. These organelles produce adenosine triphosphate (ATP), the energy currency that powers phototransduction (the conversion of light into electrical signals). By age 40, retinal mitochondrial function has declined by approximately 70 per cent compared to its peak (Gkotsi et al., 2014, Experimental Eye Research). ATP production falls, and photoreceptor cells struggle to maintain their signalling capacity.

This decline is not evenly distributed. Cone cells (responsible for colour vision and fine detail) are more affected than rods because they have higher metabolic demands. The result is a gradual loss of colour contrast sensitivity and reduced visual acuity, even in the absence of specific eye disease.

Accumulated Oxidative Damage

The retina is exposed to constant light-induced oxidative stress. Over decades, reactive oxygen species damage mitochondrial DNA, lipids, and proteins. The ageing retina produces less of the antioxidant enzymes needed to neutralise these free radicals, creating a vicious cycle of declining function.

Glen Jeffery’s Groundbreaking Research

Professor Glen Jeffery at the UCL Institute of Ophthalmology has led the most significant research programme in this field. His work has fundamentally changed our understanding of how light wavelengths interact with retinal mitochondria.

The 2020 Landmark Study

Jeffery’s team published a pilot study in The Journals of Gerontology: Series A (2020) demonstrating that just three minutes of 670 nm deep red light exposure in the morning improved colour contrast sensitivity by 20 per cent in participants aged 40 and over. Rod sensitivity (low-light vision) also improved by 20 per cent on average.

The study was small (24 participants) but elegantly designed: each participant’s untreated eye served as its own control. Improvements were sustained for at least one week after a single exposure.

The Mitochondrial Mechanism

The proposed mechanism centres on cytochrome c oxidase (CCO), the terminal enzyme in the mitochondrial electron transport chain. CCO has peak absorption bands at approximately 620 nm and 670 nm. When 670 nm photons are absorbed by CCO, the enzyme’s activity increases, boosting ATP production.

In retinal cells that are starved of energy due to age-related mitochondrial decline, this ATP boost is sufficient to restore function to a measurable degree. Jeffery has described it as “recharging the batteries” of ageing cells (Shinhmar et al., 2020).

Morning Timing Matters

A follow-up study by Shinhmar et al. (2022, Scientific Reports) revealed that the time of day matters enormously. Morning exposure (8-9 AM) produced significant improvements in colour contrast sensitivity, while afternoon exposure had no measurable effect.

The researchers attributed this to the circadian rhythmicity of mitochondrial function. Mitochondria have their own circadian patterns of activity, and the electron transport chain is more responsive to photonic stimulation during the morning uptick in metabolic activity. This finding has important practical implications: you should use red light on your eyes in the morning, not in the evening.

The 2024 Replication

Powner et al. (2024, Aging Cell) replicated these findings in a larger cohort and confirmed the wavelength specificity. Only 670 nm produced consistent improvements; shorter red wavelengths (450 nm, 510 nm) served as controls and showed no effect. The study also confirmed that benefits were specific to participants over 40 — younger participants showed no change, consistent with the hypothesis that the therapy is restoring function lost to age-related decline rather than enhancing already-optimal mitochondria.

Red Light Therapy and Specific Eye Conditions

Age-Related Macular Degeneration (AMD)

AMD is the leading cause of vision loss in adults over 50 in the UK. It involves progressive damage to the macula — the central region of the retina responsible for sharp, detailed vision.

Merry et al. (2017) conducted a clinical trial using 670 nm LED photobiomodulation on patients with dry AMD. After 12 weeks of treatment (3 minutes per session, twice weekly), treated patients showed improved visual acuity and reduced drusen volume (the yellow deposits beneath the retina that characterise AMD) (Retina, 37(6):1107-1113).

A larger multicentre trial (LIGHTSITE I) by Markowitz et al. (2020) confirmed that photobiomodulation using a combination of 590 nm, 660 nm, and 850 nm wavelengths improved best-corrected visual acuity in dry AMD patients, with benefits sustained at 6 months (Canadian Journal of Ophthalmology, 55(1):21-27). The follow-up LIGHTSITE II trial showed that repeated treatment cycles maintained the benefits.

Myopia (Short-Sightedness)

Repeated low-level red light (RLRL) therapy has emerged as one of the most promising interventions for childhood myopia progression, particularly in research from China where myopia rates have reached epidemic proportions.

Jiang et al. (2022) published a randomised controlled trial in Ophthalmology involving 264 children aged 8-13. Those receiving 3 minutes of 650 nm red light twice daily showed a 54.2 per cent reduction in myopia progression over 12 months compared to controls. Axial length elongation (the physical stretching of the eyeball that causes myopia) was also significantly reduced.

Xiong et al. (2023) conducted a meta-analysis of RLRL studies (Asia-Pacific Journal of Ophthalmology) confirming that red light therapy is effective at slowing myopia progression with a good safety profile. The proposed mechanism involves choroidal thickening — the red light stimulates increased blood flow to the choroid (the vascular layer behind the retina), which mechanically resists axial elongation.

It is worth noting that RLRL for myopia uses a focused beam delivered through a desktop device that the child looks into, rather than a standard panel or mask. This is a distinct clinical application requiring purpose-built equipment.

Presbyopia (Age-Related Near-Vision Loss)

Presbyopia — the progressive loss of near-focusing ability that typically begins in the mid-40s — is primarily caused by hardening of the crystalline lens. However, the ciliary muscle that controls lens shape is also affected by age-related energy decline.

While no large-scale trials have specifically targeted presbyopia with photobiomodulation, the improvements in overall visual function reported by Jeffery’s group suggest that mitochondrial restoration in the ciliary body and retina may partially offset presbyopic symptoms. Anecdotal reports from participants in the UCL studies noted improved near-vision clarity, though this was not a primary outcome measure.

This remains an area where more targeted research is needed.

Diabetic Retinopathy

Tang et al. (2014) demonstrated in animal models that 670 nm photobiomodulation reduced retinal inflammation and preserved photoreceptor function in diabetic rats (Diabetes, 63(11):3944-3954). The mechanism involved suppression of complement-mediated inflammation in the retinal vasculature. Human trials are ongoing but results have not yet been published.

The Protocol: How to Use Red Light for Vision

Morning Eye Protocol

Based on the UCL research, the optimal approach is straightforward:

• Wavelength: 670 nm (deep red). This is not the same as the 660 nm commonly used for skin — the 10 nm difference matters for retinal mitochondria
• Duration: 3 minutes per session
• Timing: Morning only, ideally between 8-9 AM
• Frequency: 3 times per week minimum
• Distance: Device-dependent, but the light intensity reaching the eye should be gentle — you are not trying to deliver high irradiance to the retina
• Eyes: Open, looking towards the light source (not staring directly at the LED from close range)

What Devices to Use

This is where caution is essential. Most consumer red light therapy panels are designed for skin and muscle treatment and output irradiance levels that are far too high for direct eye exposure.

For eye-specific protocols:

• Purpose-built devices (such as those used in the LIGHTSITE trials) deliver calibrated doses at safe irradiance levels
• Low-power 670 nm LED devices can work if you maintain appropriate distance (typically 30-50 cm)
• Do not use a high-power panel at close range with your eyes open — the irradiance at 5-10 cm from a 200W panel could exceed safe levels for retinal exposure

If using a standard red light panel, position yourself at a sufficient distance that the light feels comfortable — not bright or glaring. The Jeffery studies used remarkably low energy doses (approximately 40 mW/cm2 at the corneal surface for 3 minutes).

Eye Safety: Critical Considerations

Red light therapy for vision is one area where safety protocols genuinely matter. The retina is irreplaceable tissue.

What Is Safe

• 670 nm at low irradiance (under 50 mW/cm2 at the eye) for 3 minutes has an established safety record across multiple clinical trials
• Indirect exposure from panels used for body treatment (where eyes are not the target) is generally safe at normal treatment distances
• Red LED masks used for facial skin treatment deliver low enough irradiance through closed eyelids to pose minimal risk

What Is Not Safe

• Direct staring into high-power LEDs or lasers at close range — this can cause retinal burns
• Extended exposure times beyond those used in published research — more is not better for retinal tissue
• Near-infrared wavelengths (850 nm) for direct eye treatment — while beneficial for tissue behind the eye, these wavelengths can heat the lens and are not recommended for direct ocular exposure without clinical supervision
• Blue and green wavelengths at high intensity can accelerate macular damage, particularly in those with existing AMD

Red Flags — Stop Immediately If

• You experience pain, prolonged afterimages, or visual disturbance during or after treatment
• Your vision becomes temporarily blurred beyond a brief adjustment period
• You notice flashes of light or new floaters after treatment

What the Evidence Does Not Yet Support

Transparency about limitations is important:

• Red light therapy will not restore vision lost to advanced AMD, glaucoma, or retinal detachment. These conditions involve structural damage that photobiomodulation cannot reverse.
• It is not a replacement for prescription glasses or contact lenses. The improvements measured in studies are real but modest — typically 10-20 per cent improvement in specific contrast sensitivity measures.
• Long-term data beyond 12-18 months is limited. We do not yet know whether benefits are sustained with ongoing treatment or whether they plateau.
• Individual results vary considerably. Some participants in the UCL studies showed marked improvement; others showed minimal change.

Combining Red Light with Other Eye Health Strategies

Red light therapy works best as part of a broader approach to eye health:

Nutrition: Lutein and zeaxanthin (found in leafy greens and egg yolks) accumulate in the macula and provide antioxidant protection. The AREDS2 formula (vitamins C, E, zinc, lutein, zeaxanthin) is recommended for those at risk of AMD progression.

Blue light management: Reducing evening blue light exposure supports retinal health and circadian rhythm — which, as the Shinhmar study showed, is directly relevant to mitochondrial responsiveness.

Outdoor time: For children at risk of myopia, spending 90+ minutes outdoors daily is one of the strongest protective factors. Red light therapy for myopia is an adjunct, not a replacement for time outdoors.

Regular eye examinations: An optometrist can detect early signs of AMD, glaucoma, and diabetic retinopathy before symptoms appear. Photobiomodulation is a complement to, not a substitute for, professional eye care.

Frequently Asked Questions

Can I use red light therapy if I have glaucoma? There is limited evidence on photobiomodulation for glaucoma specifically. Some animal studies suggest neuroprotective effects on retinal ganglion cells, but human data is insufficient to make recommendations. Consult your ophthalmologist before use.

Will red light therapy improve my night vision? The UCL research showed improvements in scotopic (low-light) sensitivity, suggesting that rod cell function can be enhanced. However, improvements are modest and are most pronounced in those over 40 with measurable age-related decline.

Can I use a red light therapy mask for my eyes? LED masks designed for facial skin treatment typically deliver 630-660 nm light at relatively low irradiance. Using these with eyes closed is generally safe but is not the same as the 670 nm, eyes-open, morning-specific protocol used in the vision research. The benefits for retinal function from masks used this way are unclear.

How soon will I notice improvement? The UCL studies detected measurable changes within one week of a single 3-minute exposure. However, these were measured with sensitive laboratory instruments. Subjective improvements that you notice in daily life may take several weeks of consistent use.

The Bottom Line

The evidence that 670 nm red light can improve age-related visual decline is among the most robust in all of photobiomodulation research. The mechanism is well characterised (mitochondrial restoration via cytochrome c oxidase), the effect is reproducible across multiple studies, and the protocol is remarkably simple — 3 minutes of deep red light in the morning.

For myopia in children, repeated low-level red light therapy represents a genuinely exciting development, with large randomised trials showing clinically meaningful reductions in progression.

The caveats are real: this is not a cure for eye disease, the improvements are modest in absolute terms, and long-term data is still being gathered. But as a safe, inexpensive, and evidence-based intervention for supporting visual function as you age, red light therapy deserves serious attention.

This article is for informational purposes only and does not constitute medical advice. Consult a qualified eye care professional before using red light therapy for any eye condition.